ERBB2 and neoplasm: Monoclonal antibodies targeting the extracellular domain of HER2 raised in cell lines expressing high HER2 levels showed promise in their ability to inhibit tumor cell proliferation in vitro (42–44) leading to eventual development of a humanized form (45) currently in use as the approved agent trastuzumab.